$SNSS Definitive Merger Agreement CASE STUDY

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies

Leading institutional investors committed a total of $105 million in private financings with Viracta

Combined company expected to have approximately $120 million cash balance following the close of the merger

intends to be listed on the Nasdaq Global Market under the ticker symbol “VIRX.”

Viracta plans to initiate a registration trial for the treatment of EBV-positive lymphoma in the first half of 2021, and also plans to initiate a Phase 1b/2 trial in EBV-positive solid tumors in 2021.

The transaction is expected to close in the first quarter of 2021.

finance.yahoo.com/news/sunesis-pharmaceuticals-viracta-therapeutics-announce-123000277.html